Menu
Live
Market Overview
Live indices, gainers & losers
Market Pulse
AI-curated live updates
Market Movers
Top gainers & losers by cap
Market Signals
Value, momentum & analyst signals
Smart Money
Insider & congress trades
Hedge Funds
What 63 elite funds bought & sold
52-Week Highs
Stocks breaking out to new highs
52-Week Lows
Beaten-down stocks near support
High Beta
Stocks that move more than the market
Earnings Calendar
Upcoming earnings dates
Daily
Research
Invest
LIVE
OPKO Health, Inc.
OPK
NASDAQ·Healthcare·Biotechnology·Mkt cap $1.2B
$1.52
▼ -0.65%
View full research view
Our plain-language verdict, the thesis, risk factors, and what is changing about the business.
View research view52-Week Range
$0.98 - $1.61
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 14.2% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Large-scale clinical laboratory network with established physician relationships and recurring revenue base
- Proprietary long-acting therapeutic protein technology platform enabling differentiated drug candidates
- Diversified revenue streams across diagnostics and pharmaceuticals reducing business concentration risk
- International pharmaceutical platforms providing geographic diversification and emerging market exposure
- Integrated diagnostics-pharma model enabling companion diagnostics and clinical trial synergies
Bear Case
1 risk
- Average volatility.
Growth
Stable outlook
Expansion of BioReference Laboratories testing volume driven by aging population and preventive healthcare trends
Value
Deep value opportunity - significant discount to Life Sciences Tools peers
Momentum
Hot
+34.2% over 3m
Quality
Stable
Solid business
Dividend
None
No dividend
Smart-money signal
Who's buying OPK right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Apr 29, 2026
APR 28, 2026
Reported EPS of -$0.07 vs -$0.07 consensus (0.0% surprise). Revenue of $124.2M vs $130.5M expected (-4.8%).
EPS surprise · last 4Q
1 of 1 beats
Q2 26
0.0%
Next: Apr 29, 2026
Revenue trend · last 8Q
—
—
+1%
-14%
-14%
-13%
-19%
-17%
Q2 24
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
$182.2M
$173.6M
$183.6M
$150.0M
$156.8M
$151.7M
$148.5M
$124.2M
Margins · last 8Q
Gross
—
Operating
—
Profit
-44.2%
Wall Street consensus
1 analyst · 0% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
0%
Hold
100%
Sell
0%
Median Price Target
—
Latest: Barrington · Apr 29, 2026